Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Johnson and Johnson
Harvard Business School
Medtronic
Dow

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Filgrastim - Biologic Drug Details

See Plans and Pricing

« Back to Dashboard

Summary for filgrastim
Tradenames:1
Patents:187
Applicants:1
BLAs:1
Suppliers: see list1
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for filgrastim

US Patents for filgrastim

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   See Pricing SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) 2033-03-11 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   See Pricing 2038-10-10 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   See Pricing University of the Sciences of Philadelphia (Philadelphia, PA) 2034-11-21 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   See Pricing Washington University (St. Louis, MO) 2034-04-01 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   See Pricing 2038-10-10 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   See Pricing 2036-04-01 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Supplementary Protection Certificates for filgrastim

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2010 013 Romania   See Pricing PRODUCT NAME: ELTROMBOPAG; NATIONAL AUTHORISATION NUMBER: RO EU/1/10/612/001, RO EU/1/10/612/002, RO EU/1/10/612/003, RO EU/1/10/612/004, RO EU/1/10/612/005, RO EU/1/10/612/006; DATE OF NATIONAL AUTHORISATION: 20100311; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/10/612/001, EMEA EU/1/10/612/002, EMEA EU/1/10/612/003, EMEA EU/1/10/612/004, EMEA EU/1/10/612/005, EMEA EU/1/10/612/006; DATE OF FIRST AUTHORISATION IN EEA: 20100311
5/2003 Austria   See Pricing PRODUCT NAME: PEGFILGRASTIM
2014 00047 Denmark   See Pricing PRODUCT NAME: SILTUXIMAB; REG. NO/DATE: EU/1/14/928/001-002 20140527
0687 Netherlands   See Pricing PRODUCT NAME: SILTUXIMAB; REGISTRATION NO/DATE: EU/1/14/928/001-002 20140527
2014000084 Germany   See Pricing PRODUCT NAME: SILTUXIMAB; REGISTRATION NO/DATE: EU/1/14/928 20140522
2003 Austria   See Pricing PRODUCT NAME: PEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/02/228/001 20020822
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Boehringer Ingelheim
Harvard Business School
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.